Blood immune profile in patients with multiple sclerosis treated with ocrelizumab


  • Ocrelizumab treatment resulted in depletion of B cells and a changed T cell profile, marked by a decrease in serum neurofilament light (sNfL) levels in people with primary progressive multiple sclerosis (PPMS).

Why this matters

  • Ocrelizumab is the only disease-modifying treatment (DMT) approved in PPMS, a disease course which is typically unresponsive to DMT intervention.

  • Ocrelizumab is an anti-CD20 antibody that is understood to selectively deplete B cells; however, a subset of CD3+ T cells is also known to express CD20 and the effect of ocrelizumab on these cells and other immune cell types in people with PPMS is unknown.